Verapamil effect on COPD

Phase 1

• Conditions: Chronic obstructive pulmonary disease.; Diseases of the respiratory system; J00-J99

• Registration Number: IRCT20170210032478N1
• Lead Sponsor: ational Research Institute of Tuberculosis and Lung Diseases

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

All ICU- admitted COPD patients

Exclusion Criteria

pregnancy
sever hepato renal dysfunction
AV block or arrythmia
EF less than 40%
verapamil hypersensitivity
beta-adrenergic receptor drugs
QT disorders in patients
Bradycardia
co- administration of Digoxin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Arterial Oxygenation Blood gaz. Timepoint: 20 minutes after taking the medication or placebo for 3 days, Q 12 h. Method of measurement: Arterial Blood Gaz.;BORG scale. Timepoint: 20 minutes after taking the medication or placebo for 3 days, Q 12 h. Method of measurement: Tacking History.